Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial (Q40239715)

18 September 2017

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial (English)

1 reference

18 September 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

7

Luis Fayad

0 references

Jason R Westin

6

Jason Westin

1 reference

18 September 2017

24

Jorge Romaguera

1 reference

18 September 2017

10

Yasuhiro Oki

1 reference

18 September 2017

8

Felipe Samaniego

1 reference

18 September 2017

3

Hubert Chuang

1 reference

18 September 2017

Fredrick B Hagemeister

5

Frederick Hagemeister

1 reference

18 September 2017

22

L Jeffrey Medeiros

1 reference

18 September 2017

13

Krystle Nomie

1 reference

María Auxiliadora Badillo-Viloria

18 September 2017

12

Maria Badillo

1 reference

18 September 2017

19

Ken H Young

1 reference

18 September 2017

23

Richard Champlin

1 reference

18 September 2017

Nicolaus A Wagner-Bartak

4

Nicolaus Wagner-Bartak

1 reference

18 September 2017

Michael L Wang

1

1 reference

18 September 2017

Hun Lee

2

1 reference

18 September 2017

Francesco Turturro

9

1 reference

18 September 2017

Wendy Chen

11

1 reference

18 September 2017

Maria DeLa Rosa

14

1 reference

18 September 2017

Donglu Zhao

15

1 reference

18 September 2017

Laura Lam

16

1 reference

18 September 2017

Alicia Addison

17

1 reference

18 September 2017

Hui Zhang

18

1 reference

18 September 2017

Shaoying Li

20

1 reference

18 September 2017

David Santos

21

1 reference

18 September 2017

Leo Zhang

25

1 reference

18 September 2017

27 November 2015

1 reference

Lancet Oncology Commission

18 September 2017

1 reference

18 September 2017

17

1 reference

18 September 2017

48-56

1 reference

18 September 2017

1

1 reference

Advances in the understanding of mantle cell lymphoma

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

How to manage mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900438-6

7 January 2021

10.1016/S1470-2045(15)00438-6

Identifiers

DOI

1 reference

18 September 2017

1 reference